About Us

Who We Are

BioGraphene is a global biotech startup dedicated to developing novel graphene-based nanomedicines for multiple indications. With the headquarters and core R&D facilities located in Suwon, South Korea, we are a research oriented company with origins at Seoul National University and have operated a US Office as a legal entity in the state of California since June 2020.

  • Pioneer biomedical innovation for a healthier and better world

  • Advance graphene-based technology to save and improve people’s lives

  • Integrity, collaboration, passion, innovation

Established with support of Seoul Nat. Uni. Bio-MAX/N-Bio Tech. Commercialization Support Project

February | 2017

History

Opened R&D Center

July | 2018

April | 2019

Closed Series A financing

February | 2020

Moved HQ to Suwon, Korea

June | 2020

Established US office in Los Angeles

Yongseok Choi appointed CEO of BioGraphene

October | 2020

Built pilot manufacturing facility of Graphene Quantum Dots

May | 2021

Licensed graphene nanostructure-based composition patent for neurodegenerative diseases from Seoul National University and Johns Hopkins University

March | 2022

Leadership Team

Scientific Advisors

  • Byung Hee Hong, PhD

    Founder/ Professor of Chemistry, Seoul National University

  • Daehee Kang, MD/PhD

    Professor of Preventive Medicine, College of Medicine, Seoul National University

  • Yhun Yhong Sheen, PhD

    Honorary Professor, College of Pharmacy, Ewha Womans University

  • Donghoon Kim, PhD

    Professor of Pharmacology, College of Medicine, Dong-A University

  • Wade Zeno, PhD

    Professor of Chemical Engineering and Material Science, University of Southern California